Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis

Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy. Despite high response rates to these combination therapies, most patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurrish, Katie H., Su, Yongwei, Patel, Shraddha, Ramage, Cassandra L, Carter, Jenna L., Edwards, Holly, Buck, Steven A., Wiley, Sandra E., Hüttemann, Maik, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Bao, Xun, Li, Jing, Yang, Jay, Boerner, Julie, Hou, Zhanjun, Al-Atrash, Gheath, Konoplev, Sergej N, Busquets, Jonathan, Tiziani, Stefano, Matherly, Larry H., Taub, Jeffrey W., Konopleva, Marina, Ge, Yubin, Baran, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168457/
https://www.ncbi.nlm.nih.gov/pubmed/37162954
http://dx.doi.org/10.21203/rs.3.rs-2843025/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168457/
https://www.ncbi.nlm.nih.gov/pubmed/37162954
http://dx.doi.org/10.21203/rs.3.rs-2843025/v1

Ejemplares similares